Schwarz UI - Search Results

1

Induction of intestinal P-glycoprotein by St John's wort reduces the oral bioavailability of talinolol.

Schwarz UI, Hanso H, Oertel R, Miehlke S, Kuhlisch E, Glaeser H, Hitzl M, Dresser GK, Kim RB, Kirch W. Schwarz UI, et al. Clin Pharmacol Ther. 2007 May;81(5):669-78. doi: 10.1038/sj.clpt.6100191. Epub 2007 Mar 28. Clin Pharmacol Ther. 2007. PMID: 17392718 Clinical Trial.

2

[Use of drugs by women in the federal Saxony district based on survey data].

Krappweis J, Schwarz U, Kirch W. Krappweis J, et al. Gesundheitswesen. 1996 Sep;58 Suppl 2:115-9. Gesundheitswesen. 1996. PMID: 9019252 German.

3

Drug information services: initial experiences in Dresden.

Schwarz UI, Krappweis J, Stoelben S, Kirch W. Schwarz UI, et al. Eur J Clin Pharmacol. 1998 Oct;54(8):667-8. doi: 10.1007/s002280050532. Eur J Clin Pharmacol. 1998. PMID: 9860157 No abstract available.

4

Unexpected effect of verapamil on oral bioavailability of the beta-blocker talinolol in humans.

Schwarz UI, Gramatté T, Krappweis J, Berndt A, Oertel R, von Richter O, Kirch W. Schwarz UI, et al. Clin Pharmacol Ther. 1999 Mar;65(3):283-90. doi: 10.1016/S0009-9236(99)70107-4. Clin Pharmacol Ther. 1999. PMID: 10096260 Clinical Trial.

5

Regional drug information service.

Schwarz UI, Stoelben S, Ebert U, Siepmann M, Krappweis J, Kirch W. Schwarz UI, et al. Int J Clin Pharmacol Ther. 1999 Jun;37(6):263-8. Int J Clin Pharmacol Ther. 1999. PMID: 10395116

6

P-glycoprotein inhibitor erythromycin increases oral bioavailability of talinolol in humans.

Schwarz UI, Gramatté T, Krappweis J, Oertel R, Kirch W. Schwarz UI, et al. Int J Clin Pharmacol Ther. 2000 Apr;38(4):161-7. doi: 10.5414/cpp38161. Int J Clin Pharmacol Ther. 2000. PMID: 10783825 Clinical Trial.

7

Outpatient costs of osteoporosis in a national health insurance population.

Krappweis J, Rentsch A, Schwarz UI, Krobot KJ, Kirch W. Krappweis J, et al. Among authors: schwarz ui. Clin Ther. 1999 Nov;21(11):2001-14. doi: 10.1016/S0149-2918(00)86745-4. Clin Ther. 1999. PMID: 10890269

8

Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans.

Dickmann LJ, Rettie AE, Kneller MB, Kim RB, Wood AJ, Stein CM, Wilkinson GR, Schwarz UI. Dickmann LJ, et al. Among authors: schwarz ui. Mol Pharmacol. 2001 Aug;60(2):382-7. doi: 10.1124/mol.60.2.382. Mol Pharmacol. 2001. PMID: 11455026

9

Identification of functionally variant MDR1 alleles among European Americans and African Americans.

Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI, Taylor A, Xie HG, McKinsey J, Zhou S, Lan LB, Schuetz JD, Schuetz EG, Wilkinson GR. Kim RB, et al. Among authors: schwarz ui. Clin Pharmacol Ther. 2001 Aug;70(2):189-99. doi: 10.1067/mcp.2001.117412. Clin Pharmacol Ther. 2001. PMID: 11503014

10

Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine.

Dresser GK, Bailey DG, Leake BF, Schwarz UI, Dawson PA, Freeman DJ, Kim RB. Dresser GK, et al. Among authors: schwarz ui. Clin Pharmacol Ther. 2002 Jan;71(1):11-20. doi: 10.1067/mcp.2002.121152. Clin Pharmacol Ther. 2002. PMID: 11823753 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

84 results

Search Page

Filters